News

Protalix has completed New Drug Application (NDA) submission with the FDA for Taliglucerase Alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of gaucher’s disease.

Sangart has initiated dose-finding study designed to evaluate the safety and efficacy of MP4OX treatment, plus standard of care, in severely injured trauma patients with lactic acidosis due

Sanofi-aventis has signed a strategic research alliance agreement with the California Institute of Technology (Caltech) in Pasadena, CA. The goal of the research collaboration, which will be known

Osteologix anticipates of filing a marketing application in 2011 in the EU for strontium therapy, NB S101 (Strontium Malonate). If successful, this is expected to be Osteologix’ first

NanoPacific (NPH) has acquired an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement

Ranbaxy and Nippon Chemiphar (NC) have announced the dissolution of their joint venture ‘Nihon Pharmaceutical Industry Co Ltd’ (NPI), in Japan. This follows an agreement between the two

Alexion has presented new data, which demonstrates the severe clinical burden of paroxysmal nocturnal hemoglobinuria (PNH) and the clinical benefits of Soliris (eculizumab) in 44 patients with no

Trubion Pharmaceuticals and Facet Biotech have presented the positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at

Novo Nordisk and ZymoGenetics has announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, and broad intellectual property rights covering